Identification and characterization of novel hydrolytic degradation products of netarsudil by LC-Q-TOF-MS/MS: In silico toxicity prediction

References

• Tham, Y. C.; Li, X.; Wong, T. Y.; Quigley, H. A.; Aung, T.; Cheng, C. Y. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology 2014, 121, 2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Hoy, S. M. Netarsudil Ophthalmic Solution 0.02%: First Global Approval. Drugs 2018, 78, 389–396. DOI: 10.1007/s40265-018-0877-7.
   PubMed Web of Science ®Google Scholar
• Asrani, S.; Robin, A. L.; Serle, J. B.; Lewis, R. A.; Usner, D. W.; Kopczynski, C. C.; Heah, T.; Ackerman, S. L.; Alpern, L. M.; Asrani, S.; et al. MERCURY-1 Study Group. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am. J. Ophthalmol. 2019, 207, 248–257. DOI: 10.1016/j.ajo.2019.06.016.
   PubMed Web of Science ®Google Scholar
• Lin, C. W.; Sherman, B.; Moore, L. A.; Laethem, C. L.; Lu, D. W.; Pattabiraman, P. P.; Rao, P. V.; deLong, M. A.; Kopczynski, C. C. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J. Ocul. Pharmacol. Ther. 2018, 34, 40–51. DOI: 10.1089/jop.2017.0023.
   PubMed Web of Science ®Google Scholar
• Kahook, M. Y.; Serle, J. B.; Mah, F. S.; Kim, T.; Raizman, M. B.; Heah, T.; Ramirez-Davis, N.; Kopczynski, C. C.; Usner, D. W.; Novack, G. D.; et al. Long-Term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am. J. Ophthalmol. 2019, 200, 130–137. DOI: 10.1016/j.ajo.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Batra, M.; Gupta, S.; Nair, A. B.; Dhanawat, M.; Sandal, S.; Morsy, M. A. Netarsudil: A New Ophthalmic Drug in the Treatment of Chronic Primary Open Angle Glaucoma and Ocular Hypertension. Eur. J. Ophthalmol. 2021, 31, 2237–2244. DOI: 10.1177/11206721211008783.
   PubMed Web of Science ®Google Scholar
• Sharanya, P. S.; Rani, S. S. Development and Validation of Stability Indicating Analytical Method for the Simultaneous Estimation of Netarsudil and Latanoprost by RP-HPLC World. WJPS 2022, 10, 104–112. DOI: 10.54037/WJPS.2022.100111.
   Google Scholar
• Mehta, J.; Patel, V.; Kshatri, N.; Vyas, N. A Versatile LC Method for the Simultaneous Quantification of Latanoprost, Timolol and Benzalkonium Chloride and Related Substances in the Presence of Their Degradation Products in Ophthalmic Solution. Anal. Methods 2010, 2, 1737–1744. DOI: 10.1039/c0ay00405g.
   Web of Science ®Google Scholar
• Satyanarayana, U.; Dilshad, P.; Ramakrishna, K. Reversed-Phase Hplc Method Development and Validation of Latanoprost in Ophthalmic Solution and Identification of Unknown Impurities by LC-MS/MS. Int. J. Pharm. Technol. 2016, 8, 13941–13940.
   Google Scholar
• Padmalatha, K.; Durga, D. V.; Jagadeeswari, N. A Novel Study on rp-Hplc Method Development and Validation for Estimation of Netarsudil and Latanoprost in Api and Pharmaceutical Dosage Form. World J. Pharm. Pharm. Sci. 2021, 10, 1624–1633.
   Google Scholar
• Dharmamoorthy, G. Development and Validation of a Stability-Indicating Reverse-Phase Ultra-Performance Liquid Chromatography Method for the Simultaneous Determination of Netarsudil and Latanoprost in Bulk and Pharmaceutical Formulation. Int. J. Green Pharm. 2020, 14 (2), 179–185.
   PubMedGoogle Scholar
• Photostability Testing of New Drug Substances and Products Q1B. Proceedings of the International Conference on Harmonisation (ICH); IFPMA: Geneva, 1996.
   Google Scholar
• Stability Testing of New Drug Substances and Products Q1A (R2). Proceedings of the International Conference on Harmonisation (ICH); IFPMA: Geneva, 2003.
   Google Scholar
• World Health Organization (Ed.). WHO Expert Committee on Specifications for Pharmaceutical Preparations: Forty-Third Report; Vol. 953; World Health Organization, Geneva, 2009.
   Google Scholar
• Singh, S.; Bakshi, M. Guidance on the Conduct of Stress Tests to Determine Inherent Stability of Drugs. Pharm. Technol. Asia 2000, 24, 1–14.
   Google Scholar
• Singh, S.; Handa, T.; Narayanam, M.; Sahu, A.; Junwal, M.; Shah, R. P. A Critical Review on the Use of Modern Sophisticated Hyphenated Tools in the Characterization of Impurities and Degradation Products. J. Pharm. Biomed. Anal. 2012, 69, 148–173.
   PubMed Web of Science ®Google Scholar
• Narayanam, M.; Handa, T.; Sharma, P.; Jhajra, S.; Muthe, P. K.; Dappili, P. K.; Shah, R. P.; Singh, S. Critical Practical Aspects in the Application of Liquid Chromatography–Mass Spectrometric Studies for the Characterization of Impurities and Degradation Products. J. Pharm. Biomed. Anal. 2014, 87, 191–217.
   PubMed Web of Science ®Google Scholar
• Banerjee, P.; Eckert, A. O.; Schrey, A. K.; Preissner, R. ProTox-II: A Webserver for the Prediction of Toxicity of Chemicals. Nucleic Acids Res. 2018, 46, W257–W263. DOI: 10.1093/nar/gky318.
   PubMed Web of Science ®Google Scholar
• Kumar, N.; Devineni, S. R.; Dubey, S. K.; Kumar, P. Potential Impurities of Anxiolytic Drug, Clobazam: Identification, Synthesis and Characterization Using HPLC, LC-ESI/MSn and NMR Products. J. Pharm. Biomed. Anal. 2017, 137, 268–278. DOI: 10.1016/j.jpba.2017.01.051.
   PubMed Web of Science ®Google Scholar
• Baksam, V. K.; Nimmakayala, S.; Pocha, V. R.; Gouri, B.; Shandilya, S.; Kumar, P. Separation and Characterization of the Related Substances of Bedaquiline Fumarate Using HPLC and Spectral Methods. J. Chromatogr. Sci. 2021, 134, 1–11.
   Google Scholar